Canopy Growth Corporation (CGC, Financial) experienced a significant stock price decline of 5.25%, trading at $2.89 per share with a trading volume of 2.95677 million shares and a turnover rate of 2.42%. The stock's amplitude was noted at 6.56%. Recent financial reports show the company generated $46.18 million in revenue but reported a net loss of $96.45 million, equating to an earnings per share of -$1.08 and a gross profit of $11.60 million. The price-to-earnings ratio stands at -0.61.
In terms of analyst ratings, 11% recommend buying, 44% suggest holding, and 45% advise selling. The pharmaceutical sector, where Canopy Growth operates, saw an overall decline of 1.29%. Other active stocks in the sector include Scilex Holding Company, Procaps Group S.A., and Cumberland Pharmaceuticals.
Canopy Growth, based in Smiths Falls, Canada, produces and sells medicinal and recreational cannabis through brands like Doja and Tweed. Their non-THC products include Martha Stewart CBD skincare and Storz & Bickel vaporizers. The company has integrated its U.S. assets into Canopy USA, a separately operated holding company.
